RU2039563C1 - Method of treating patients suffering erysipelas - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: essence of this method resides in comprehensively treating patient with thypontin to be administered subcutaneously in dose of 100 kg at interval of 4 to 5 days (cure: 4 to 5 injections, each measuring 400 to 500 mcg). EFFECT: higher clinical effectiveness, shorter treatment period, prevention of complications and relapses, less pronsedness of intoxication syndrome, and acceleration of reverse development of local manifestation of disease. 1 tbl

Description

 The invention relates to medicine, in particular to the section of infectious diseases, infections of the external integument, and can be used to treat patients with erysipelas.

A known method of treating patients with erysipelas, including the use of methyluracil in combination with levamisole and sodium nucleinate [1]
The disadvantages of this method include the incomplete relief of complications and relapses of the disease, the need for repeated courses of antibiotic therapy with frequent relapsing erysipelas, as well as the possibility of allergic reactions.

Also known is a method of treating patients with erysipelas using a combination of reaferon and mefenamic acid [2]
The disadvantages of this method is the possibility of nausea, diarrhea, abdominal pain, allergic phenomena (skin itching, rash) after taking mefenamic acid. This drug is contraindicated in gastric ulcer and duodenal ulcers and inflammatory diseases of the gastrointestinal tract. In addition, this method does not completely prevent the occurrence of complications and relapses, does not cancel repeated courses of antibiotics for often recurring erysipelas.

 A known method of treating patients with erysipelas using a combination of sodium nucleinate, splenin and glycyram as immunomodulators. The listed funds were prescribed in the acute period of the disease: sodium nucleinate 0.5 g three times a day, glyciram 0.1 g three times a day, splenin 2 ml intramuscularly daily per day for 7-10 days.

 The main disadvantages of this method are the incomplete relief of complications and relapses of the disease, the need for repeated courses of antibiotic therapy for recurring erysipelas, frequent trauma to the skin associated with the introduction of splenin, therefore, an increased risk of infection with hepatitis B viruses and HIV infection. Glycyram is contraindicated in organic heart lesions and impaired liver and kidney function.

 The aim of the invention is to increase clinical efficacy and reduce treatment time, the prevention of complications and relapses of the disease.

 This is achieved due to the fact that in the method of treating patients with erysipelas using immunomodulators, thymoptin is used in complex therapy, administered subcutaneously at a dose of 100 μg per injection (in a vial of 100 μg) with an interval of 4-5 days, a course of 4-5 injections (400 -500 mcg).

 PRI me R. 1. Patient D. 68 years old, a pensioner. He entered the clinic 03/26/90 about recurrent erysipelas of the left lower leg, erythematous form, moderate severity (8th relapse). The primary erysipelas occurred in 1980. From January to February, the month of 1990 twice suffered relapses of the disease.

 Concomitant diseases: hypertension, post-traumatic left-sided sciatic nerve neuritis, chronic thrombophlebitis of superficial veins of the lower extremities, epidermophytosis of the feet.

 Along with conventional therapy, including the appointment of penicillin in a daily dose of 4 million units. diphenhydramine, eskusan, ascorbic acid, Kalanchoe juice, the patient was injected subcutaneously at a dose of 100 μg per injection at a 4-day interval with thymoptin, which was dissolved in 1 ml of a 0.9% sodium chloride solution before use. The first two injections were made in a hospital, the next outpatient. The course was 5 injections (500 mcg).

 In the hospital, after the first injection, pronounced positive dynamics were noted: the duration of the fever was 3 days, weakness 2. Local manifestations stopped in the first 3 days. All of the above made it possible to reduce the course of penicillin treatment to 5 days, to refuse in the future from a second course of antibiotic therapy. Dispensary observation showed no relapse for 10 months.

 PRI me R 2. Patient G. 20 years old, telegraph operator. Was admitted to the 2nd infectious ward of the 7th city clinical hospital in Simferopol on March 16, 1990 with a diagnosis of recurring erysipelas of the right lower leg, bullous-hemorrhagic form, moderate severity (3rd relapse). Suffers from a long-standing disease of 5 years. Last relapse suffered 2 months ago.

 Concomitant disease: Shereshevsky-Turner syndrome.

 The patient was prescribed: penicillin in a daily dose of 6 million units. furazolidone, diphenhydramine, ascorutin, Kalanchoe juice. At the same time, thymoptin was administered subcutaneously with an interval of 5 days at a dose of 100 μg per injection, the course was 5 injections (500 μg).

 General toxic effects disappeared after 3 days from the start of treatment, erysipelas, local hyperthermia, soreness stopped on the 12th day of treatment, bullae and hemorrhage after 6 days from the time of occurrence. The treatment was well tolerated, there were no complications. The patient was discharged in satisfactory condition. The length of stay in the hospital was 25 days. No relapse was observed within 10 months of follow-up.

 PRI me R 3. Patient M., 34 years old, a milling machine operator, was in the hospital for 9 days with primary bullous-hemorrhagic erysipelas of the right shoulder and forearm of moderate severity.

05.30.90 entered, the (on the fourth day of the disease) with a temperature of ^about 39, with a sharply demarcated ardent erythema and edema, bullae, tachycardia, muffled heart sounds. He became acutely ill several days after injuring the fingers of his right hand during the execution of a production task. Onset of the disease was accompanied by chills, a rapid rise in body temperature ^to 40 °, muscle pain, a burning sensation in the right arm and shoulder. After 6 hours, rapidly increasing erythema and edema appeared, spreading to the shoulder region and to the upper third of the forearm; on the third day of the disease, serous blisters appeared. On the 5th day of illness, when the patient was in the hospital, point hemorrhages appeared, the contents of the bullae acquired a crimson-cyanotic color.

 From the day of admission, treatment has been started: penicillin 1 million units. 4 times a day, furazolidone 0.1 g 4 times a day, diphenhydramine 0.05 g 3 times a day, ascorutin 1 tablet 3 times a day, symptomatic. Locally applied Kalanchoe juice.

 Along with the listed drugs, timoptin was prescribed. Before use, thymoptin was dissolved in 1 ml of 0.9% sodium chloride solution and was administered subcutaneously at a dose of 100 μg per injection with an interval of 4 days. The course was 5 injections (500 mcg). The patient received two injections in the hospital, the rest in the clinic at the place of residence.

 When implementing the proposed method, the main clinical manifestations of the disease disappear faster (table), complications and relapses are prevented, the average length of hospital stay of a patient is reduced (table).

Claims (1)

 METHOD FOR TREATING SICK YEARS by using immunomodulators, characterized in that thymoptin is used in complex therapy, administered at a dose of 100 μg per injection subcutaneously with an interval of 4-5 days, a course of 4-5 injections.

Images